The axon-myelin unit in development and degenerative disease

Stassart, R. M., Möbius, W., Nave, K.-A. and Edgar, J. M. (2018) The axon-myelin unit in development and degenerative disease. Frontiers in Neuroscience, 12, 467. (doi: 10.3389/fnins.2018.00467) (PMID:30050403) (PMCID:PMC6050401)

[img]
Preview
Text
164923.pdf - Published Version
Available under License Creative Commons Attribution.

3MB

Abstract

Axons are electrically excitable, cable-like neuronal processes that relay information between neurons within the nervous system and between neurons and peripheral target tissues. In the central and peripheral nervous systems, most axons over a critical diameter are enwrapped by myelin, which reduces internodal membrane capacitance and facilitates rapid conduction of electrical impulses. The spirally wrapped myelin sheath, which is an evolutionary specialisation of vertebrates, is produced by oligodendrocytes and Schwann cells; in most mammals myelination occurs during postnatal development and after axons have established connection with their targets. Myelin covers the vast majority of the axonal surface, influencing the axon's physical shape, the localisation of molecules on its membrane and the composition of the extracellular fluid (in the periaxonal space) that immerses it. Moreover, myelinating cells play a fundamental role in axonal support, at least in part by providing metabolic substrates to the underlying axon to fuel its energy requirements. The unique architecture of the myelinated axon, which is crucial to its function as a conduit over long distances, renders it particularly susceptible to injury and confers specific survival and maintenance requirements. In this review we will describe the normal morphology, ultrastructure and function of myelinated axons, and discuss how these change following disease, injury or experimental perturbation, with a particular focus on the role the myelinating cell plays in shaping and supporting the axon.

Item Type:Articles
Additional Information:Work in our labs is funded by the Multiple Sclerosis Society UK (Ref 038) and European Union’s Horizon 2020 research and innovation programme under ZikaPLAN grant agreement No 734584 (JE); DFG (SPP 1757) and the European Research Council (MyeliNANO) (K-AN); ERA-NET for Research Programs on Rare Diseases E-RARE-3 (01GM1605) and the German network on Charcot-Marie-Tooth Disease (CMT-NET, 01GM1511C) (RS).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Edgar, Professor Julia
Authors: Stassart, R. M., Möbius, W., Nave, K.-A., and Edgar, J. M.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Frontiers in Neuroscience
Publisher:Frontiers Media
ISSN:1662-4548
ISSN (Online):1662-4548
Copyright Holders:Copyright © 2018 Stassart, Möbius, Nave and Edgar
First Published:First published in Frontiers in Neuroscience 12:467
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
736191ZikaPLANHugh WillisonEuropean Commission (EC)734584III -IMMUNOLOGY